<DOC>
	<DOC>NCT02120417</DOC>
	<brief_summary>This is a randomized, double-blind, placebo controlled clinical trial comparing the overall survival of women with advanced or metastatic HER2-negative breast cancer who receive treatment with capecitabine in combination with ruxolitinib versus those who receive treatment with capecitabine alone.</brief_summary>
	<brief_title>A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Histologically or cytologically confirmed HER2negative adenocarcinoma of the breast Locally advanced (Stage 3B) or metastatic (Stage 4) disease Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2 Received up to 2 prior chemotherapy regimens (not including neoadjuvant/adjuvant therapy) for advanced or metastatic disease Subjects with hormonereceptor positive tumors must have failed available appropriate lines of hormonal therapy ≥ 2 weeks elapsed from the completion of previous treatment regimen and must have recovered or be at a new stable baseline from any related toxicities Radiographically measurable or evaluable disease An mGPS of 1 or 2 as defined below: Criteria: 1. mGPS of 1: CRP &gt; 10 mg/L and albumin ≥ 35 g/L 2. mGPS of 2: CRP &gt; 10 mg/L and albumin &lt; 35 g/L Received prior treatment with capecitabine for metastatic disease Received more than 2 prior chemotherapy regimens for advanced or metastatic disease (not including neoadjuvant/adjuvant therapy) Unknown hormonereceptor status Ongoing radiation therapy, radiation therapy administered within 2 weeks of enrollment Inadequate renal, hepatic or bone marrow function</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Breast Cancer</keyword>
</DOC>